Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor

Journal of Virology

Volumn 86, Issue 24, 2012, Pages 13313-13323

  Todorovic, Biljana ^a,b   Hung, Katherine ^a,b   Massimi, Paola ^c   Avvakumov, Nikita ^a,b   Dick, Frederick A ^a,b   Shaw, Gary S ^a   Banks, Lawrence ^c   Mymryk, Joe S ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN; CULLIN 2; PROTEIN E7; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL CYCLE ARREST; CELL SURFACE; CONSERVED REGION 3; CONTROLLED STUDY; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN MOTIF; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BINDING SITES; CELL CYCLE; CELL LINE; DNA PRIMERS; HUMANS; MODELS, MOLECULAR; PAPILLOMAVIRUS E7 PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; RETINOBLASTOMA PROTEIN; TWO-HYBRID SYSTEM TECHNIQUES;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84870686974     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01637-12     Document Type: Article

References (53)

1. Adams A, Gottschling DE, Kaiser CA, Stearns T. 1997. Methods in yeast genetics. Cold Spring Harbor Press, Cold Spring Harbor, NY.
2. Androphy EJ, Hubbert NL, Schiller JT, Lowy DR. 1987. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J. 6:989-992.
3. Avvakumov N, Torchia J, Mymryk JS. 2003. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 22:3833-3841.
4. Banks L, et al. 1987. Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J. Gen. Virol. 68(Pt 5):1351-1359.
5. Barbosa MS, et al. 1990. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 9:153-160.
6. Berezutskaya E, Bagchi S. 1997. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J. Biol. Chem. 272:30135-30140.
7. Bodily JM, Mehta KP, Cruz L, Meyers C, Laimins LA. 2011. The E7 open reading frame acts in cis and in trans to mediate differentiation-dependent activities in the human papillomavirus type 16 life cycle. J. Virol. 85:8852-8862.
8. Bodily JM, Mehta KP, Laimins LA. 2011. Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Cancer Res. 71:1187-1195.
9. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:4620-4624.
10. Brehm A, et al. 1998. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597-601.
11. Brehm A, et al. 1999. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 18:2449-2458.
12. Cecchini MJ, Dick FA. 2011. The biochemical basis of CDK phosphorylation-independent regulation of E2F1 by the retinoblastoma protein. Biochem. J. 434:297-308.
13. Centers for Disease Control and Prevention. 2010. FDA licensure of bivalent human papillomavirus vaccine (HPV2, cervarix) for use in females and updatedHPVvaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 59:626-629.
14. Chellappan S, et al. 1992. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl. Acad. Sci. U. S. A. 89:4549-4553.
15. Chemes LB, Sanchez IE, Smal C, de Prat-Gay G. 2010. Targeting mechanism of the retinoblastoma tumor suppressor by a prototypical viral oncoprotein. Structural modularity, intrinsic disorder and phosphorylation of human papillomavirus E7. FEBS J. 277:973-988.
16. Chen J, Saha P, Kornbluth S, Dynlacht BD, Dutta A. 1996. Cyclinbinding motifs are essential for the function of p21CIP1. Mol. Cell. Biol. 16:4673-4682.
17. Cheng CY, Blanchette P, Branton PE. 2007. The adenovirus E4orf6 E3 ubiquitin ligase complex assembles in a novel fashion. Virology 364:36-44.
18. Cheng CY, et al. 2011. The E4orf6/E1B55K E3 ubiquitin ligase complexes of human adenoviruses exhibit heterogeneity in composition and substrate specificity. J. Virol. 85:765-775.
19. Classon M, Harlow E. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2:910-917.
20. Dawar M, Deeks S, Dobson S. 2007. Human papillomavirus vaccines launch a new era in cervical cancer prevention. CMAJ 177:456-461.
21. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27.
22. Dick FA, Dyson N. 2003. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol. Cell 12:639-649.
23. Dick FA, Sailhamer E, Dyson NJ. 2000. Mutagenesis of the pRB pocket reveals that cell cycle arrest functions are separable from binding to viral oncoproteins. Mol. Cell. Biol. 20:3715-3727.
24. Dyson N. 1998. The regulation of E2F by pRB-family proteins. Genes Dev. 12:2245-2262.
25. Dyson N, Howley PM, Munger K, Harlow E. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937.
26. Edmonds C, Vousden KH. 1989. A point mutational analysis of human papillomavirus type 16 E7 protein. J. Virol. 63:2650-2656.
27. Funk JO, et al. 1997. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11:2090-2100.
28. Future II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915-1927.
29. Giarre M, et al. 2001. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. J. Virol. 75:4705-4712.
30. Gietz RD, Schiestl RH, Willems AR, Woods RA. 1995. Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast 11:355-360.
31. Gillison ML, et al. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 92:709-720.
32. Gonzalez SL, Stremlau M, He X, Basile JR, Munger K. 2001. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 75:7583-7591.
33. Goodwin EC, DiMaio D. 2000. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc. Natl. Acad. Sci. U. S. A. 97:12513-12518.
34. Goodwin EC, et al. 2000. Rapid induction of senescence in human cervical carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 97:10978-10983.
35. Helt AM, Galloway DA. 2001. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 75:6737-6747.
36. Huh K, et al. 2007. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81:9737-9747.
37. Jeon S, Allen-Hoffmann BL, Lambert PF. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69:2989-2997.
38. Jones DL, Thompson DA, Munger K. 1997. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239:97-107.
39. Kalejta RF, Brideau AD, Banfield BW, Beavis AJ. 1999. An integral membrane green fluorescent protein marker, Us9-GFP, is quantitatively retained in cells during propidium iodide-based cell cycle analysis by flow cytometry. Exp. Cell Res. 248:322-328.
40. Liu X, Clements A, Zhao K, Marmorstein R. 2006. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 281:578-586.
41. Longworth MS, Dyson NJ. 2010. pRb, a local chromatin organizer with global possibilities. Chromosoma 119:1-11.
42. Massimi P, Shai A, Lambert P, Banks L. 2008. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene 27:1800-1804.
43. Morris EJ, Dyson NJ. 2001. Retinoblastoma protein partners. Adv. Cancer Res. 82:1-54.
44. Nevins JR. 1992. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429.
45. Ohlenschlager O, et al. 2006. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene 25:5953-5959.
46. Patrick DR, Oliff A, Heimbrook DC. 1994. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem. 269:6842-6850.
47. Phelps WC, Munger K, Yee CL, Barnes JA, Howley PM. 1992. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol. 66:2418-2427.
48. Romanowski B. 2011. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum. Vaccin. 7:161-169.
49. Schneider-Gadicke A, Schwarz E. 1987. Transcription of human papillomavirus type-18 DNA in human cervical carcinoma cell lines. Haematol. Blood Transfus. 31:380-381.
50. Sherr CJ. 2000. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60:3689-3695.
51. Smotkin D, Wettstein FO. 1987. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol. 61:1686-1689.
52. Todorovic B, et al. 2011. Systematic analysis of the amino acid residues of human papillomavirus type 16 E7 conserved region 3 involved in dimerization and transformation. J. Virol. 85:10048-10057.
53. White EA, et al. 2012. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. Proc. Natl. Acad. Sci. U. S. A. 109:E260-E267.